is a division of theAssociation for Accessible Medicines,formerly known as GPhA, who works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars.
Interested in getting involved?
The Biosimilars Council routinely participates in and hosts events to promote knowledge around the advancement of biosimilars in the United States.
See below for information on our annual conference and a link to download our Handbook.
Put simply, biosimilars are biologic medicines that are highly similar to a corresponding brand biologic. Biosimilars offer a safe, effective, and affordable alternative for patients. They are approved by the U.S. Food and Drug Administration (FDA) and improve patient access to life-saving medicines.